Crescent Biopharma, Inc. CBIO
13.97 USD +0.05 (+0.36%)
Nov 11, 2026, 10:24 AM EST
13.87 Day range 14.20
8.72 52-week range 27.41
- YTD
- +17.79%
- 1 year
- +5.43%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $36 price target.
benzinga.com Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027 Global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027Phase 1/2 trial of CR-003 (SKB105), an…
benzinga.com HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.
benzinga.com Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
benzinga.com Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
benzinga.com Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
benzinga.com Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of…
benzinga.com Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms Undisclosed Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
benzinga.com This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.- benzinga.com Crescent Biopharma Announces Trial In Progress Presentation For ASCEND Study Of CR-001, At ASCO 2026 Annual Meeting; Multiple CR-001 Clinical Data Readouts Anticipated Beginning In Q1 2027 Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
benzinga.com Crude Oil Down 3%; Chevron Posts Mixed Q1 Results Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Esperion, Five9, Atlassian soared while Summit, Crescent, LendingTree fell.
benzinga.com Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%. Tech shares jumped 1.6%, energy stocks fell 1.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of…
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock- benzinga.com Crescent Biopharma Files Prospectus For Resale Of Up To ~19.7M Shares By Selling Securityholders From Private Placement And Warrants This prospectus relates to the proposed resale or other disposition by the selling securityholders identified herein (the "Selling Securityholders") of up to (i) 13,664,251 (the "Private Placement…
benzinga.com HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and lowers the price target from $25 to $22.- benzinga.com Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(4.01) per share which missed the analyst consensus estimate of $(2.31) by 73.44 percent. This is a 79.69 percent increase over losses…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35 Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.
- benzinga.com Crescent Biopharma Announces Regulatory Clearances Of IND Applications For CR-001, PD-1 X VEGF Bispecific Antibody, And CR-003, ITGB6-Targeted ADC, For Treatment Of Advanced Solid Tumors CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with…
benzinga.com What's Happening With Crescent Biopharma Stock Today? Cresent Biopharma shares were trading higher Thursday but have since reversed and begun trading lower after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical.- benzinga.com Market-Moving News for December 4th PATH: 15% | UiPath shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance with its midpoint above estimates. SNOW: -9% | Snowflake
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Crescent Biopharma Secures $185M Private Placement; Investors To Purchase 13.8M Ordinary Shares At $13.41 Or Pre-Funded Warrants At $13.409 Private Placement FinancingCrescent also announced today that it entered into a securities purchase agreement for a private investment of securities to institutional and other accredited investors…
- benzinga.com Sichuan Kelun-Biotech And Crescent Biopharma Partner To Develop, Commercialize Oncology Therapeutics; Cos To Advance CR-001, PD-1 x VEGF Bispecific Antibody, And SKB105 In Global Markets And China Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and ChinaCollaboration designed to accelerate…
- benzinga.com Crescent Biopharma Q3 EPS $(1.27) Beats $(1.98) Estimate Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.98) by 35.92 percent.
- benzinga.com Crescent Biopharma To Present Preclinical Data From CR-001 Antibody For Solid Tumor Tumors At Society For Immunotherapy Of Cancer Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $25 price target.
benzinga.com This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Jefferies Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $26 Jefferies analyst Akash Tewari initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $26.
benzinga.com This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - benzinga.com HC Wainwright & Co. Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $25 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $25.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Wedbush Initiates Coverage On Crescent Biopharma with Outperform Rating, Announces Price Target of $27 Wedbush analyst Robert Driscoll initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announces Price Target of $27.
benzinga.com Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com Stifel Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $28 Stifel analyst Stephen Willey initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $28.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity U.S. futures were higher on Wednesday as oil futures tumbled after Donald Trump called for an "Unconditional Surrender" by Iran late Tuesday.
benzinga.com Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - benzinga.com Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session